🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

INFEX Therapeutics Excited to share our licensing deal in India for clinical development of MET-X our novel metallobetalactamase (MBL) inhibitor. MBL mechanism of resistance is an enormous problem in India & SE Asia & a rising problem EU & USA. MBL mechanism is a key pipeline priority for WHO

Venus Remedies Secures Exclusive Licensing Rights from UK-Based Infex Therapeutics to Develop and Commercialize MET-X in India! A special thanks to Mr. Saransh Chaudhary, Mr. Kamal Joshi, Mr. Anmol Aggarwal and team VMRC for achieving this significant milestone! INFEX Therapeutics

Read the latest article from Professor Dame Sally Davies (UK Special Envoy on AMR) and Nikolaj Gilbert (President & CEO of PATH). There is a looming antibiotic emergency, and the time for global action is now: telegraph.co.uk/global-health/…

Infex Therapeutics is attending #BioTrinity tomorrow & Wednesday in London, hosted by OBN_UK . If you wish to meet with us, please send a meeting request via the partnering app. Find out more at biotrinity.com

See the below interesting piece in The Guardian, which looks at why #AntimicrobialResistance #AMR is often misunderstood, and views on animal farming with the rise of resistant pathogens emerging from antibiotic use in animals: theguardian.com/commentisfree/…

Our Head of BD, Carl Curran, had a great day at #BioTrinity earlier this month— full of high-quality partnering meetings and strong interest in our best-in-class anti-infectives. A big thanks to all who connected! #AntiInfectives #LifeSciences

Infex agrees collaboration with Asian clinical trials network, ADVANCE-ID Memorandum of Understanding signed to investigate hospital-acquired drug-resistant infections in Asia: infextx.com/infex-agrees-c…

.INFEX Therapeutics agrees collaboration with Asian clinical trials network, ADVANCE-ID ✒️ MOU signed to investigate hospital-acquired drug-resistant infections in Asia 🏥Clinical trials to explore use of MET-X alongside existing therapies londonstockexchange.com/news-article/m…

Very excited to work with Asian ADVANCE-ID network to plan clinical trials of our novel metallo-beta-lactamase (MBL) inhibitor, MET-X. Antimicrobials targeting MBL mechanism of Gram negative bacterial resistance to antibiotics is key gap in pipeline. David Paterson INFEX Therapeutics

A novel drug that could become the first new class of antibiotics in 50 years is set to enter late-stage human trials. The drug targets antimicrobial resistance, and works in a completely different way to existing antibiotics: telegraph.co.uk/news/2025/05/2…

Today, we're attending Barclays Health Elevate at Barclays HQ in Canary Wharf. If you're around, come and say hello!